A detailed history of Seizert Capital Partners, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Seizert Capital Partners, LLC holds 56,400 shares of GILD stock, worth $3.86 Million. This represents 0.2% of its overall portfolio holdings.

Number of Shares
56,400
Previous 58,605 3.76%
Holding current value
$3.86 Million
Previous $4.75 Million 12.98%
% of portfolio
0.2%
Previous 0.25%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 01, 2024

SELL
$71.58 - $87.29 $157,833 - $192,474
-2,205 Reduced 3.76%
56,400 $4.13 Million
Q4 2023

Feb 07, 2024

SELL
$73.27 - $83.09 $1.92 Million - $2.18 Million
-26,178 Reduced 30.88%
58,605 $4.75 Million
Q3 2023

Nov 06, 2023

BUY
$73.94 - $80.67 $16,932 - $18,473
229 Added 0.27%
84,783 $6.35 Million
Q2 2023

Jul 27, 2023

SELL
$76.01 - $86.7 $661,591 - $754,636
-8,704 Reduced 9.33%
84,554 $6.52 Million
Q1 2023

May 09, 2023

SELL
$77.31 - $88.08 $2.07 Million - $2.36 Million
-26,738 Reduced 22.28%
93,258 $7.74 Million
Q4 2022

Jan 30, 2023

SELL
$62.32 - $89.47 $735,189 - $1.06 Million
-11,797 Reduced 8.95%
119,996 $10.3 Million
Q3 2022

Nov 02, 2022

SELL
$59.54 - $68.01 $33,640 - $38,425
-565 Reduced 0.43%
131,793 $8.13 Million
Q2 2022

Aug 04, 2022

BUY
$57.72 - $65.01 $395,093 - $444,993
6,845 Added 5.45%
132,358 $8.18 Million
Q1 2022

May 03, 2022

BUY
$57.92 - $72.58 $33,246 - $41,660
574 Added 0.46%
125,513 $7.46 Million
Q4 2021

Feb 08, 2022

BUY
$64.88 - $73.64 $64,685 - $73,419
997 Added 0.8%
124,939 $9.07 Million
Q3 2021

Nov 03, 2021

BUY
$67.69 - $73.03 $203 - $219
3 Added 0.0%
123,942 $8.66 Million
Q2 2021

Aug 05, 2021

BUY
$63.47 - $69.35 $230,967 - $252,364
3,639 Added 3.02%
123,939 $8.53 Million
Q1 2021

May 05, 2021

BUY
$60.0 - $68.46 $7.22 Million - $8.24 Million
120,300 New
120,300 $7.78 Million
Q4 2020

Feb 08, 2021

SELL
$56.65 - $64.55 $576,923 - $657,377
-10,184 Closed
0 $0
Q2 2020

Aug 06, 2020

SELL
$72.34 - $84.0 $18.8 Million - $21.8 Million
-260,098 Reduced 96.23%
10,184 $784,000
Q1 2020

May 05, 2020

SELL
$62.63 - $80.22 $21.5 Million - $27.5 Million
-343,053 Reduced 55.93%
270,282 $20.2 Million
Q4 2019

Feb 10, 2020

BUY
$61.62 - $67.78 $1.73 Million - $1.91 Million
28,151 Added 4.81%
613,335 $39.9 Million
Q3 2019

Nov 07, 2019

SELL
$62.51 - $69.0 $1.2 Million - $1.32 Million
-19,122 Reduced 3.16%
585,184 $37.1 Million
Q2 2019

Aug 06, 2019

SELL
$61.87 - $69.38 $2.71 Million - $3.04 Million
-43,877 Reduced 6.77%
604,306 $40.8 Million
Q1 2019

May 07, 2019

BUY
$62.53 - $70.05 $4.02 Million - $4.5 Million
64,231 Added 11.0%
648,183 $42.1 Million
Q4 2018

Feb 08, 2019

SELL
$60.54 - $79.0 $4.08 Million - $5.32 Million
-67,389 Reduced 10.35%
583,952 $36.5 Million
Q3 2018

Nov 09, 2018

BUY
$71.28 - $78.92 $1.21 Million - $1.34 Million
16,972 Added 2.68%
651,341 $50.3 Million
Q1 2018

May 10, 2018

BUY
$72.84 - $88.8 $52,736 - $64,291
724 Added 0.11%
634,369 $47.8 Million
Q4 2017

Feb 12, 2018

BUY
$71.15 - $83.52 $2.89 Million - $3.4 Million
40,656 Added 6.86%
633,645 $45.4 Million
Q3 2017

Oct 31, 2017

SELL
$72.11 - $85.47 $2.76 Million - $3.27 Million
-38,280 Reduced 6.06%
592,989 $48 Million
Q2 2017

Aug 09, 2017

BUY
N/A
631,269
631,269 $44.7 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $85.7B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Seizert Capital Partners, LLC Portfolio

Follow Seizert Capital Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Seizert Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Seizert Capital Partners, LLC with notifications on news.